Navigation Links
ENMD in Medical News

EntreMed Reports Second Quarter 2009 Financial Results

... ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six...

EntreMed Reports First Quarter 2009 Financial Results

... ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial res...

EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results

... ROCKVILLE, Md., March 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for t...

EntreMed Focuses on Development of ENMD-2076

...agement Realigned to Provide Full Support for Clinical Activities ROCKVILLE, Md., Dec. 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company announced today plans to focus the Company's resources on its most promising near-term product candidate, E...

EntreMed Reports Clinical Program Progress and Company Update

... ROCKVILLE, Md., Nov. 12, /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, reported corporate and clini...

EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

... ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program

... Additional Resources to Accelerate ENMD-2076 Partnering Efforts ROCKVILLE, Md., Aug. 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed to Present at the BIO 2008 Annual International Convention

... ROCKVILLE, Md., June 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference

... ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

Dr. Ronald E. Cape to Retire from EntreMed Board of Directors

... ROCKVILLE, Md., April 7, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the retireme...
ENMD in Medical Technology

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...ded Clinical Program Now Includes Solid and Hematological Malignancies ROCKVILLE, Md., June 1 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for i...

EntreMed Presents Initial Clinical Results for ENMD-2076

...ug Designation and Canadian CTA Accelerate ENMD-2076 Program Momentum ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced recent devel...

EntreMed Receives New Patent for 2-Methoxyestradiol Analogs

... Patent Covers Compositions and Methods ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

... Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

...pounds Demonstrate Potent Antitumor Activity in a Variety of Tumor Types ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting

...ral Presentation During the "New Drugs on the Horizon 2" Special Session ROCKVILLE, Md., April 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced it will pres...

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

...elective Kinase Inhibitor Phase 1 Trial in Advanced Cancer Patients ROCKVILLE, Md., April 9, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Commences Continuous Dosing Clinical Trial For MKC-1

... Phase 1 Study to be Conducted in Advanced Cancer Patients ROCKVILLE, Md., April 2, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers

... Multi-Center Clinical Trial to be Conducted in Canada ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the commence...

EntreMed to Present at The New York Society of Security Analysts Industry Conference

... ROCKVILLE, Md., Dec. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....
ENMD in Biological Technology

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

...nical Program Adds Leukemia Clinical Study and Orphan Drug Designation ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for three of its clinical...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed to Present at the New York Society of Security Analysts Industry Conference

... ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Compa...

EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial

... Phase 2 Randomized Study Under Consideration ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Reports Third Quarter 2008 Financial Results

... ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for t...

Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models

... ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publicat...

EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

... ROCKVILLE, Md., Oct. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed to Present at BioPartnering Europe Conference

... ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H...

EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market

... ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Reports Second Quarter 2008 Financial Results

... EntreMed to Conduct Update Call on Tuesday, August 12, 2008 ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial res...
Other Tags
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
Other Contents